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Abstract
Appropriately activated mononuclear phagocytes mediate contact-dependent tumoricidal activity. Adhesion structures
involved in contact-dependent tumor cytotoxicity have not been defined. The present study was aimed at identifying the
adhesion structure involved in the tumoricidal activity of cisplatin-activated murine peritoneal macrophages. Tumor cells of
 .different histological origin were used as targets in a 24-h cytotoxicity assay. Anti-CD18 LFA-1b substantially inhibited
macrophage cytotoxicity whereas anti-LFA-1a marginally inhibited macrophage-mediated cytotoxicity. When combined
together, almost complete inhibition of tumoricidal activity was observed. Activated macrophages showed augmented
binding to target cells and anti-LFA MAb inhibited the binding of resting and activated macrophages to target cells.
Cisplatin augmented the expression of LFA-1a and b integrins and LPS had no effect as assessed by immunoprecipitation.
These results implicate that in cisplatin activated macrophages LFA-1a and b integrins are important molecules in
contact-dependent tumoricidal activity. q 1998 Elsevier Science B.V.
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1. Introduction
When appropriately activated, cells of monocyte–
macrophage lineage can kill nucleated mammalian
w xcells extracellularly 1 . The cytotoxic activity is usu-
ally exerted preferentially on neoplastically trans-
w xformed vs. untransformed cells 2–4 . Macrophages
possess a remarkable capacity to distinguish between
non-transformed and transformed cells probably via
certain undefined cell surface molecules.
) Corresponding author.
Except in the case of tumor cell extremely suscep-
tible to lysis by soluble mediators released by
mononuclear phagocytes, optimal expression of
macrophage tumoricidal activity usually requires con-
w xtact between effector and target cells 2–4 .
Macrophage-mediated cytotoxicity may, therefore,
depend on mechanisms involving the cell membranes
w xof macrophages, target cells or both 5,6 . It has also
been suggested that the contact between macrophage
and the target cells represents a firm binding of target
cells to macrophages and probably is the first step in
w xthe cytolytic destruction of the target 6–8 .
w xCisplatin cis-dichlorodiamineplatinum II , a
widely used anti-cancer drug, activates the
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macrophages and other effector cells to tumoricidal
state and thus functions as a potent biological re-
w xsponse modifier 9–13 . Earlier studies from our lab-
oratory have shown that when tumor cells are co-in-
cubated with cisplatin-activated macrophages, both
macrophage and tumor cell extend cytoplasmic ex-
tensions towards each other establishing cytoplasmic
bridges which ultimately lead to their fusion and lysis
w xof the tumor cell 14 . The adhesion molecules in-
volved in the cytotoxic interaction between activated
macrophages and the tumor targets have not been
defined. Here we report that leucocyte function asso-
 .ciated antigen 1 LFA-1 plays a crucial role in
cisplatin stimulated macrophage-mediated tumorici-
dal activity. LFA-1 is a heterodimeric molecule con-
stituted by an a chain and a b chain. Experiments
were performed to determine the relative importance
of the 2 types of structure expressed on macrophages
using anti-LFA-1a and b MAbs reactive with func-
tional epitopes of the molecules.
2. Materials and methods
2.1. Mice
Inbred strain of pathogen free BALBrc of either
sex aged 8–10 weeks were used for obtaining peri-
toneal macrophages.
2.2. Cell culture and reagents
 . L929 murine fibroblast cell line , YAC-1 Molo-
.ney leukemia virus induced lymphoma cell line and
 .P815 murine mastocytoma cell line obtained from
National Facility for Animal Cell and Tissue Culture
 .Pune, India were used as tumor target cells for
estimating macrophage-mediated cytotoxicity.
125  .Na I specific activity: 103.3 mCirml was ob-
tained from Bhabha Atomic Research Centre
 .Bombay, India . Anti-LFA-1a and anti-LFA-1b
were obtained from The Center of Blood Research,
Boston, MA 02115, USA. All other reagents, includ-
ing culture medium RPMI 1640 were purchased from
 .Sigma St. Louis, MO, USA . All the reagents and
culture medium were free from endotoxin contamina-
tion as determined by the limulus amoebocyte lysate
 .assay sensitivity limit, -0.1 ngrml .
2.3. Isolation and acti˝ation of peritoneal
macrophages
Macrophage monolayers were prepared as de-
w xscribed by Singh et al. 9 . Peritoneal exudate cells
 .PEC were harvested by peritoneal lavage using
chilled serum free RPMI-1640 culture medium. PEC
were added to each well of a 96-well tissue culture
 .plate ArS Nunc, Denmark . After 2 h of incubation
at 378C in a CO incubator, the non-adherent cells2
were removed by vigorous washing with warm serum
free culture medium. Approximately 1.5=105 cells
adhered to each well. In the adherent cell population,
more than 95% cells were macrophages as deter-
mined by morphology, non-specific esterase staining
and phagocytosis of latex beads. Macrophages were
cultured in complete medium for 18–24 h to form a
well spread monolayer. For activation macrophages
 5 .1=10 cellsrwell in 96 well tissue culture plate
were incubated with medium alone or containing
 .cisplatin 10 mgrml , in presence or absence of
 .  .anti-LFA-1a CD11a and anti-LFA-1b CD18
 .MAb 2 mgrml for 24 h as indicated in the results.
After incubation, the culture supernatants were col-
lected, centrifuged at 250=g for 10 min, followed
by passage through a 0.22 mm membrane filter.
These cell-free supernatants were assayed for re-
leased IL-1, TNF and nitric oxide activity. The
macrophage monolayers were washed and used for
macrophage-mediated cytotoxicity.
2.4. Macrophage-mediated cytotoxicity
Cytotoxicity was assayed by measuring release of
w xradioactivity as described by Sodhi et al. 15 . Target
 6 .cells P815, YAC-1 and L929, 1=10 rml in expo-
nential growth phase were incubated in medium con-
w3 xtaining 1 mCirml of H thymidine for 24 h. The
target cells were then washed three times with warm
medium and plated in the wells containing effector
 .cells at an effector:target E:T cell ratio of 10:1.
After 24 h of co-incubation, cell-free culture super-
natants were harvested and an aliquot was counted
for radioactivity in a liquid scintillation counter LKB,
.Bromma, Sweden . The percentage of macrophage-
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mediated cytotoxicity was calculated using the for-
mula:
EyS
% cytotoxicitys100=
TyS
Where, E represents the radioactivity released in
culture wells containing effectorq target cells; S rep-
resents spontaneous release, i.e., radioactivity release
in the cultures of target cell alone; and T represents
total release, i.e., radioactivity released from target
cell lysed with 1 N NaOH. Spontaneous release was
consistently less than 10% of the total release.
2.5. Assay of IL-1 acti˝ity
IL-1 activity was assayed by a standard thymocyte
w xproliferation assay as described by Mizel 16 . Thy-
mocytes obtained from 4- to 8-week old C HrHeJ3
mice were incubated at a concentration of 1.5=106
cellsrwell in a 96-well plastic tissue culture plate
with medium containing submitogenic doses of con-
 . canavalin A 1 mgrml and 2-mercaptoethanol 2=
y5 .  .10 M along with test supernatants 50% vrv .
The cultures were incubated for 72 h at 378C in a
CO incubator. Thymocyte proliferation was assayed2
by pulse-labeling the cells 18 h prior to termination
w3 xwith 0.5 mCirwell of H thymidine. At the end of
the incubation period, the cells were washed three
times with serum-free medium and lysate was pre-
 .pared with 1% SDS wrv . 100 ml aliquot of the
lysate were counted for radioactivity in LKB liquid
scintillation counter. Interleukin-1 activity was ex-
w3 xpressed as H thymidine incorporation in counts per
 .minute cpm . The IL-1 activity was compared to a
 .standard recombinant IL-1 preparation NIBSC .
2.6. Assay of TNF acti˝ity
Cell free culture supernatants obtained from treated
and untreated macrophages were assayed for released
TNF activity by the method given by Mathews and
w x 4Neale 17 . A total of 3=10 L929 cellsrwell along
 .with test supernatants 50% vrv in 96 well culture
plate was incubated in complete RPMI 1640 medium
 .containing actinomycin-D 2 mgrml . After 18 h, the
test sample was removed and viable adherent cells
were fixed with 5% formaldehyde in PBS followed
by staining with 1% aqueous crystal violet. The
optical density was read at 540 nm on Emax mi-
 .croplate reader Molecular Devices, USA . The TNF
activity was expressed in terms of percentage cyto-
toxicity, which was calculated using the following
formula:
CyE
% cytotoxicitys =100
C
where C represents absorbance of wells containing
target cells incubated with medium alone and E
represents absorbance of wells containing target cells
incubated with test samples.
2.7. Nitrite assay for estimation of nitric oxide
production
The concentration of stable nitrite, an end product
from nitric oxide generated by effector macrophages
was determined in the supernatants collected from
treated and untreated macrophages by the method of
w xDing et al. 18 based on Griess reaction. A total of
100 ml culture supernatants was mixed with an equal
volume of Griess reagent one part of 1% sulphanil-
amide in 2.5% H PO plus one part of 0.1%3 4
naphthyl-ethylene-diamine dihydrochloride in dis-
tilled water; two parts being mixed together within 12
.h of use and kept chilled and kept at room tempera-
ture for 10 min in a 96-well immunoplate. The
absorbance at 540 nm was then determined on a
Molecular Devices Emax microplate reader. Nitrite
 5 .content nmolr10 cells was quantified by extrapo-
lation from a sodium nitrite standard curve in each
experiment. In all the experiments, nitrite content in
the wells containing medium without cells was also
measured and subtracted.
2.8. Macrophage target cell binding assay
The binding assay was carried out as described by
w xSodhi and Singh 19 . Treated or untreated
macrophage monolayers were washed and incubated
w3 xin fresh medium containing H thymidine-labeled
P815 cells in an E:T cell ratio of 10:1. After 2 h of
incubation, the macrophage monolayers were washed
2–3 times with serum free medium and digested with
0.25% SDS. The lysates were assayed for residual
radioactivity by liquid scintillation counter. The tar-
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get cell binding was calculated by the following
formula:
E
total binding %s =100
T
where EsCPM bound to monolayer and Ts total
CPM of added target cells.
2.9. Iodination and immunoprecipitation of LFA-1
molecules
Immunoprecipitation of both a and b chains of
LFA-1 was carried out according to method de-
w xscribed by Markwell and Fox 20 . The macrophage
 6 .monolayers in 12 well plate 1.5=10 cellsrwell
were incubated in medium alone or with cisplatin 10
.mgrml for 24 h. After incubation, the monolayers
were washed once with PBS, and were processed for
iodination of membrane proteins with 125I-labeled
 .NaI 300 mCirwell . After iodination, the cells were
 .washed with cold NaI 5 mM in PBS and were lysed
 . in 1 ml of lysis buffer LB 0.14 M NaCl, 0.01 M
.Tris, 0.1% NaN , 1% Triton X-100, pH 7.8 contain-3
ing PMSF. Transferred the lysed cells to eppendorf
tubes and centrifuged at 10 000=g for 15 min at 48C
to collect the supernatants. A total of 25 ml of
anti-LFA-1a or anti-LFA-1b MAbs was added to
300 ml of the lysed cell proteins to immunoprecipi-
tate LFA-1a and b molecules for 16–18 h at 48C.
After incubation, 75 ml of 1:3 diluted anti-mouse
 .IgG-agarose Sigma was added to it and was mixed
by continuous rocking for 4 h at 48C. The immune
complex was washed twice with cold LBrPMSFrNaI
 .1r100 volume of 500 mM NaI to LBrPMSF and
 .once with PBSrNaI 5 mM . Finally, the immune
complex was lysed in 100 ml of 3% SDS reducing
sample buffer with bromo phenol blue. The mixture
was heated at 958C for 5 min before being subjected
to 10% SDS-PAGE. For autoradiography, X-ray plate
was exposed to dried gel for 8 days.
2.10. Statistical analysis
The statistical significance of difference between
the test groups were analysed by Student’s t-test
 .two-tailed . All experiments were done each in trip-
licate and repeated at least three times.
3. Results
3.1. Effect of anti-LFA-1 antibodies on the tumorici-
dal acti˝ity of murine macrophages stimulated with
cisplatin
Fig. 1 depicts a representation of the results ob-
tained out of a series of experiments carried out,
 .aimed to study the effect of anti-LFA-1a CD11a
 .and anti-LFA-1b CD18 MAbs on the tumoricidal
activity of the cisplatin treated murine peritoneal
macrophages against several tumor targets. LFA-1 is
a heterodimer molecule constituted by an a chain
and a b chain. Experiments were performed to deter-
mine the relative importance of the two types of
structure expressed on macrophage using anti-LFA-
1a and b MAbs reactive with functional epitopes of
the molecules. The cytotoxic activity of cisplatin-
treated macrophages was markedly inhibited in the
presence of anti-LFA-1a MAb. Whereas, there was
Fig. 1. Inhibition of macrophage-mediated tumor cell lysis by
 .  .anti-CD11a LFA-1a and anti-CD18 LFA-1b MAbs. Peri-
 .toneal macrophages were incubated with cisplatin 10 mgrml
for 24 h, in presence or absence of anti-LFA-1a and b antibod-
w3 xies. Cytotoxicity was measured against H Tdr labelled L929
 .  .  .filled bars , P815 hatched bars and YAC-1 dotted bars tumor
cells in 24 h cytotoxicity assay. Anti-CD8 was used as irrelevant
antibody. SDs were less than 10% of the mean. Results are
representative of three independent experiments done in tripli-
cate.
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only a modest inhibition of cytotoxicity by anti-LFA-
1a . However, when the macrophages were incubated
with both anti-LFA-1a and b MAbs, the
macrophage-mediated tumoricidal activity was inhib-
ited in an additive manner.
3.2. Effect of anti-LFA-1a and b antibodies on the
production of TNF, IL-1 and NO by cisplatin
acti˝ated macrophages
Anti-LFA-1 antibodies did not alter the production
of cytolytic molecules by cisplatin-treated
macrophages. We checked the production of TNF,
IL-1 and NO by cisplatin-activated macrophages at
different time points in the presence or absence of
anti-LFA-1a and b antibodies. Fig. 2 shows the
results obtained at one time point. It was observed
that there was no significant effect of anti-LFA-1 a
.and b combined antibodies on the production of
IL-1, TNF and NO by cisplatin-treated macrophages
 .Fig. 2a–c .
3.3. Effect of anti-LFA-1 MAbs on binding of
acti˝ated macrophages to tumor cells
Further, we examined the effect of anti-LFA-1a
and b antibodies on the binding of activated
macrophages to tumor cells. Similar to other observa-
w xtions 2,14,21 more tumor cells bind to activated
 .  .Fig. 2. a Lack of effect of anti-LFA-1 a q b on IL-1
production by murine macrophages. Peritoneal macrophages were
 .activated with cisplatin 10 mgrml with or without anti-LFA-1
MAbs. IL-1 activity was measured in the supernatants collected
after 24 h by thymocyte proliferation assay as described in
Section 2. SDs were less than 10% of the mean and the values
 .are representative of three independent experiments. b Lack of
 .effect of anti-LFA-1 a q b on TNF production by murine
macrophages. Peritoneal macrophages were activated with cis-
 .platin 10 mgrml with or without anti-LFA-1 MAbs. TNF
activity was measured in the supernatants collected after 24 h as
described in Section 2. SDs were consistently less than 10% of
the mean. Results are representative of three independent experi-
 .  .ments done in triplicate. c Lack of effect of anti-LFA-1 a q b
on nitric oxide production by murine macrophages. Peritoneal
 .macrophages were activated with cisplatin 10 mgrml with or
without anti-LFA-1 MAbs. Nitrite was measured in the super-
natants collected after 24 h as described in Section 2. SDs were
less than 10% of the mean and the values are representative of
three independent experiments.
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macrophages than to untreated normal macrophages
 .Fig. 3 . Co-presence of anti-LFA-1a and b antibod-
ies led to significant inhibition in the binding of
untreated or cisplatin-treated macrophages to P815
cells. Anti-LFA-1 MAbs completely abolished the
enhanced binding of cisplatin treated macrophages,
suggesting that these structures account for the in-
creased adhesion of cisplatin activated macrophages
to tumor cells.
3.4. Expression of LFA-1a and LFA-1b on
macrophages upon cisplatin treatment
The dependence of macrophage tumor cell binding
on LFA-1 a and b cell adhesion molecules could be
indicative of an increase in the expression of these
cell adhesion molecules on the surface of cisplatin-
treated macrophages. Therefore, the expression of
LFA-1a and LFA-1b on murine peritoneal
macrophages was examined upon cisplatin treatment
 .Fig. 3. Effect of LFA-1 a q b on binding of cisplatin-activated
macrophages to tumor target cells. Macrophage monolayers were
 .  .incubated in medium alone v or with cisplatin 10 mgrml ;
 .  .  .’ in presence thin lines or absence thick lines of anti-LFA-1
 .a q b MAbs. After incubation, the monolayers were washed
with serum free warm medium and were co-incubated with
w3 xH Tdr labelled P815 cells at an E:T cell ratio of 10:1 for
indicated durations. Values are representative of three indepen-
dent experiment done in triplicate. SDs were consistently less
than 10% of the mean.
Fig. 4. Autoradiogram of immunoprecipitated LFA-1a Lanes 1,
.  .2 and 3 and LFA-1b Lanes 4, 5 and 6 subunits of LFA-1
molecules expressed in peritoneal macrophages treated with
 .  .medium alone Lanes 1 and 4 , cisplatin Lanes 2 and 5 or LPS
 .  6 .Lanes 3 and 6 . Macrophages 1.5=10 cells were incubated
 .with medium alone or in medium containing cisplatin 10 mgrml
 .or LPS 10 mgrml for 24 h. After incubation the cells were
washed, radioiodinated, lysed and immunoprecipitated with anti-
LFA-1a and anti-LFA-1b MAbs.
by immunoprecipitation with anti-LFA-1a and b
 .antibodies Fig. 4 . It is very clear from the auto-
 .  .radiogram Fig. 4 that cisplatin 10 mgrml treat-
ment of macrophage enhanced the expression of both
and chains of LFA-1 molecule.
4. Discussion
Mononuclear phagocytes mediate contact-depen-
dent killing of tumor cells upon exposure to appropri-
w x wate activation signals 1 . Cisplatin cis-dichlorodi-
 .xamineplatinum II , a potent anti-tumor compound,
can also be used as an immunomodulator of the
cellular immune response against neoplasia. It has
been shown that cisplatin activates murine peritoneal
macrophages, bone marrow derived macrophages,
splenic lymphocytes, human monocytes, NK cells
and lymphokine activated killer cells to tumoricidal
w xstate 9–13 . The adhesion molecules involved are
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poorly characterised. The present observations impli-
cate LFA-1 as an important cell adhesion molecules
in the tumoricidal activity of cisplatin-treated
 .macrophages. Anti-LFA-1b CD18 MAb caused
substantial inhibition of the tumoricidal activity of
murine macrophages activated with cisplatin against
target cells of different histological origins. However,
anti-LFA-1a MAb had a modest effect with respect
to the inhibition of macrophage-mediated tumoricidal
activity when used alone. However, an additive effect
was observed in combination with anti-b chain MAb.
An attempt was made to investigate the mechanism
of the inhibition of macrophage tumoricidal activity
by anti-LFA-1 antibodies. Two possibilities were
checked: first if anti-LFA-1 antibodies directly influ-
enced the cytocidal machinery of macrophages and
second, if antibodies could influence the binding of
cisplatin-treated macrophages to tumor cells.
Interestingly, it was observed that the presence of
anti-LFA-1 antibodies did not have any appreciable
effect on the production of cytocidal molecules: TNF,
IL-1 and NO by cisplatin activated macrophages.
w xBernasconi et al. 22 reported similar type of obser-
vations where he showed that anti-CD18 did not
affect TNF and IL-1 production by IFN-Y activated
monocytes. Along the same lines, anti-CD18 MAbs
did not affect the production of Oy in response to2
w xPMA 22 . The lack of inhibition of TNF production
by anti-LFA-1 MAbs is particularly noteworthy in
view of the block of killing of L929 fibroblast cells
caused by same antibodies. The L929 cells are
exquisitely sensitive to TNF. These results strongly
suggest that anti-LFA-1 MAbs do not inhibit
macrophage-mediated tumor cytotoxicity by affecting
production of effector molecules. Therefore, the rea-
son for observed inhibition of cytotoxicity might be
other than inhibition of the production of cytolytic
molecules.
LFA-1 is a non-covalently-linked heterodimer in-
w xvolved in cell to cell interaction 23 . In particular,
these molecules are important for adhesion of normal
w xmonocytes to vascular endothelium 21,24 and to
w xtumor cells 25 . Mononuclear phagocytes activated
for tumor cytotoxicity have increased capacity to
w xbind target cells 2 , an observation extended in the
present study with murine macrophages. The results
presented here show that cisplatin enhances the bind-
ing of macrophages to tumor cells and anti-LFA-1
MAbs completely abrogate the same. Strassman et al.
w x26 had already reported that anti-LFA-1 Ab inhibit
the capture of haematopoietic tumors by activated
mouse macrophages. The inhibition of the augmented
adhesion of cisplatin-activated macrophages to tumor
cells, as well as lack of any effect on production of
cytotoxic molecules, indicate that anti-LFA-1 anti-
bodies interfere in the process of macrophage cyto-
toxicity at the level of macrophage binding to target
cells. Next, we checked if cisplatin could alter the
expression of LFA-1 molecules on the surface of
macrophages. Indeed, cisplatin-treated macrophages
showed an enhanced expression of LFA-1 molecules
 .on the cell surface whereas lipopolysaccharide LPS
 .had no effect Fig. 4 . This observation could be an
additional support indicating that LFA-1 molecules
are involved in the interaction of cisplatin-treated
macrophages with tumor cells. The results reported
here demonstrate that LFA-1 adhesion pathway plays
an important role in the tumoricidal activity of cis-
platin activated macrophages, however, it does not
exclude the importance of other adhesion pathways in
the mononuclear phagocyte–tumor cell interaction,
by analogy with what is known for T and NK cells.
 .Adhesion via CD18r11a LFA-1 could allow deliv-
ery of relatively high concentrations of cytotoxic
molecules such as TNF and NO, in the area of
contact with tumor targets. It will be important to
define whether adhesion via activated LFA-1 also
delivers signals to effector or target cells which am-
plify the action of mononuclear phagocyte effector
molecules.
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